Tumor and stromal chemoresistance
PRINCIPAL INVESTIGATORS
- Maria Lourdes Farre Vallve
CLINICAL RESEARCHERS
- Nuria Ruiz Roig
PREDOCTORAL RESEARCHERS
- Natalia Molina Valdelvira
- Daniel Alvarez Villanueva
SCIENTIFIC SUPPORT
- Maria Bañuls Ferrando
- Monica Calaf Sanjuanes
- Maria Martinez Iniesta
Cancer
Oncobell
Scientific production
11
PAPERS
Average IF: 9,58
4
LED PAPERS
Average IF: 4
3 PUBLICATIONS IN FIRST DECILE
8 PUBLICATIONS IN FIRST QUARTILE
9 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Ortiz Barahona,V;Soler,M;Davalos,V;Garcia Prieto,CA;Janin,M;Setien,F;Fernandez Rebollo,I et al, Epigenetic inactivation of the 5-methylcytosine RNA methyltransferase NSUN7 is associated with clinical outcome and therapeutic vulnerability in liver cancer, Mol. Cancer, 2023;22(1):83-83, doi:10.1186/s12943-023-01785-z
- Alvarez Sierra,D;Rodriguez Grande,J;Gomez Brey,A;Bello,I;Caubet,E;Gonzalez,O;Zafon,C et al, Single cell transcriptomic analysis of Graves’ disease thyroid glands reveals the broad immunoregulatory potential of thyroid follicular and stromal cells and implies a major re-interpretation of the role of aberrant HLA class II expression in autoimmunity, J. Autoimmun., 2023;139103072-103072, doi:10.1016/j.jaut.2023.103072
- Pecharromán,I;Solé,L;Alvarez Villanueva,D;Lobo Jarne,T;Alonso Marañón,J;Bertran,J;Guillén,Y et al, I?B kinase-a coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy, Embo J., 2023;42(21):doi:10.15252/embj.2023114719,
- Amirkhah,R;Gilroy,K;Malla,SB;Lannagan,TRM;Byrne,RM;Fisher,NC;Corry,SM et al, MmCMS: mouse models’ consensus molecular subtypes of colorectal cancer., Br. J. Cancer, 2023;128(7):1333-1343, doi:10.1038/s41416-023-02157-6
- Creus Bachiller,E;Fernández Rodríguez,J;Magallón Lorenz,M;Ortega Bertran,S;Navas Rutete,S;Romagosa,C;Silva,TM et al, Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities, Mol. Oncol., 2023;doi:10.1002/1878-0261.13534
Research highlights
PROJECTS
8 Ongoing competitive projects
1 Ongoing non competitive project
PUBLISHED WORKS
1 Clinical guideline
1 Thesis
INNOVATION
2 Licenses
1 Spin off
NETWORKS
LMRN
Selected projects
- FIS22049. Identificación de vulnerabilidades terapéuticas en cáncer de ovario y pulmón analizando las vías de reparación del ADN por Excisión de Nucleótidos (NER) y Recombinación Homóloga (HR). Instituto de Salud Carlos III (ISCIII). Budget: 214.170€. 2023-2025. PI: Villanueva Garatachea, Alberto.
- FIS21070. Evaluación espacial del impacto del tratamiento neoadyuvante sobre el microambiente tumoral en las metástasis hepáticas de cáncer colorectal. Instituto de Salud Carlos III (ISCIII). Budget: 169.400€. 2022-2024. PI: GARCIA MOLLEVI, DAVID.
- 20FIS014. Genetic bases of tumor cell resitance to immune checkpoint inhibitors in orthoxenografts/ PDOX derived from three cisplatin-based treated tumors: NSCLC, bladder and ovarian cancer. Instituto de Salud Carlos III (ISCIII). Budget: 147.620€. 2020-2023. PI: Villanueva Garatachea, Alberto.
- FIS21065. Improving Outcomes of Patients with Extramedullary Multiple Myeloma. Potential Applicability of Orthoxenograft Models in the Study of Genetic Bases of Drug Resistance. Instituto de Salud Carlos III (ISCIII). Budget: 135.520€. 2022-2024. PI: Farre Vallve, Maria Lourdes.
- 19FIS027. Reprogramación de fibroblastos asociados a carcinoma intratumorales en metástasis hepáticas de carcinoma colorrectal. Instituto de Salud Carlos III (ISCIII). Budget: 111.320€. 2019-2023. PI: GARCIA MOLLEVI, DAVID.